Valeant Pharmaceuticals International (VRX) 210.42

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 3:01 PM

Valeant Pharmaceuticals International (VRX) 210.42 $VRX

4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)

Is Corning's (GLW) Q1 Earnings Likely to Surprise Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 5:31PM CDT
Corning (GLW) is set to report first-quarter 2014 results on Jan 28. Last quarter, the company posted 18.4% positive earnings surprise. Let's see how things are shaping up for this announcement.
VRX: 210.42 (+1.03), BPOP: 34.25 (-0.50), GLW: 22.52 (-0.27), THRM: 52.62 (+0.74)

Will Ecolab's (ECL) Q1 Earnings Disappoint Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 5:27PM CDT
Our proven model does not conclusively show that Ecolab Inc. (ECL) is likely to beat earnings this quarter.
VRX: 210.42 (+1.03), MRTX: 27.87 (-0.15), MEIP: 2.16 (-0.02), ECL: 115.59 (-0.26)

European Ad Comm backs expanded label for Valeant's Relistor
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 3:21PM CDT

PGNX: 6.03 (-0.38), VRX: 210.42 (+1.03)

RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
CNW Group - Fri Apr 24, 8:14AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR(®) (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
PGNX: 6.03 (-0.38), VRX: 210.42 (+1.03), VRX.TO: 255.98 (+1.76)

Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)

Will PMC-Sierra's (PMCS) Earnings Surprise this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 12:35PM CDT
PMC-Sierra Inc. (PMCS) is set to report first-quarter 2015 results on Apr 27. Last quarter, the company posted in-line results. Let's see how things are shaping up for this announcement.
VRX: 210.42 (+1.03), AWR: 39.92 (+0.30), BPOP: 34.25 (-0.50), PMCS: 8.99 (-0.25)

Roche Beats on Q1 Sales driven by Oncology & Immunology - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 9:18AM CDT
Roche Holding AG's (RHHBY) performance in the first quarter was impressive. The oncology portfolio looks solid as ever and we expect further traction in 2015 from the HER2 franchise.
VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26)

Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.32 (-0.14), VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26), MYL: 76.06 (+2.37)

After Yesterday's Rally of 2.75% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 21, 4:17PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $205.23 to a high of $211.13. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $208.30 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 210.42 (+1.03)

Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On Mylan
EP Vantage - Seeking Alpha - Tue Apr 21, 2:25PM CDT
The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma data show. And with Teva (NYSE: TEVA ) confirming its interest in ...
AGN: 240.22 (+2.88), VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16)

Will Microsoft (MSFT) Disappoint Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:50AM CDT
Microsoft Corp. (MSFT) is set to report third-quarter fiscal 2015 results on Apr 23. Last quarter, the company posted a 10.0% positive earnings surprise.
VRX: 210.42 (+1.03), BPOP: 34.25 (-0.50), LH: 126.93 (+0.55), MSFT: 47.87 (+4.53)

Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 210.42 (+1.03), SHPG: 255.11 (-0.26), ARQL: 2.12 (unch), AMPE: 2.73 (-0.16)

Will St. Jude Medical's (STJ) Earnings Miss the Mark in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 1:30PM CDT
St. Jude Medical Inc. (STJ) is slated to release its first-quarter 2015 earnings results on Apr 22. Last quarter, the company reported earnings in line with the Zacks Consensus Estimate
VRX: 210.42 (+1.03), STJ: 73.47 (-0.54), LH: 126.93 (+0.55), CGNX: 47.50 (-0.78)

Will Texas Instruments (TXN) Top Earnings Estimates in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 11:50AM CDT
We expect the semiconductor company, Texas Instruments (TXN), or "TI", to beat expectations when it reports first-quarter 2015 results on Apr 22.
VRX: 210.42 (+1.03), BPOP: 34.25 (-0.50), TXN: 54.73 (+0.01), LH: 126.93 (+0.55)

Uptrend Call Working As Valeant Pharmaceuticals International Stock Rises 39.1% (VRX)
Comtex SmarTrend(R) - Mon Apr 20, 11:26AM CDT
SmarTrend identified an Uptrend for Valeant Pharmaceuticals International (NYSE:VRX) on December 22nd, 2014 at $147.01. In approximately 4 months, Valeant Pharmaceuticals International has returned 39.05% as of today's recent price of $204.43.
VRX: 210.42 (+1.03)

Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 6:36PM CDT
Targacept, Inc. announced disappointing top-line data from a phase I/II exploratory study on its candidate TC-6499 for the treatment of diabetic gastroparesis.
CYTK: 7.25 (-0.18), VRX: 210.42 (+1.03), TRGT: 2.43 (+0.04), PFE: 35.27 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Must Decide by Dec 15 Class Suit

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Tennessee's Bold Lung Cancer Trial Signals Innovation

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Air Sealing First: Boosting Home Comfort & Efficiency

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...